110859-48-8

Basic information

• Product Name: 2-(4-BENZYL-MORPHOLIN-2-YLMETHYL)-ISOINDOLE-1,3-DIONE
• Synonyms: 2-(4-BENZYL-MORPHOLIN-2-YLMETHYL)-ISOINDOLE-1,3-DIONE;2-[(4-Benzylmorpholin-2-yl)methyl]isoindoline-1,3-dione
• CAS NO: 110859-48-8
• Molecular Formula: C₂₀H₂₀N₂O₃
• Molecular Weight: 336.39
• Mol File: 110859-48-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-BENZYL-MORPHOLIN-2-YLMETHYL)-ISOINDOLE-1,3-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BENZYL-MORPHOLIN-2-YLMETHYL)-ISOINDOLE-1,3-DIONE(110859-48-8)
• EPA Substance Registry System: 2-(4-BENZYL-MORPHOLIN-2-YLMETHYL)-ISOINDOLE-1,3-DIONE(110859-48-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 110859-48-8(Hazardous Substances Data)

Usage

General Description

2-(4-Benzyl-morpholin-2-ylmethyl)-isoindole-1,3-dione, also known as GSK563, is a chemical compound with potential therapeutic applications. It is a novel isoindoline-1,3-dione derivative that possesses anti-inflammatory and analgesic properties. GSK563 has shown promising results in preclinical studies for the treatment of inflammatory conditions such as rheumatoid arthritis and other autoimmune diseases. Additionally, its unique chemical structure and mechanism of action make it a potential candidate for further drug development and clinical trials. Overall, GSK563 represents a promising lead compound for the development of new medications for inflammatory and autoimmune disorders.

Upstream product

• 104-63-2 N-Benzylethanolamine 
• 40987-25-5 N-benzyl-2-chloromethylmorpholine 
• 1074-82-4 potassium phtalimide 

Downstream Products

• 1401233-89-3 3-chloro-2-methyl-N-(morpholine-2-ylmethyl)benzenesulfonamide 
• 1401232-07-2 methyl N-((4-benzylmorpholine-2-yl)methyl)-3-chloro-2-methylbenzenesulfonamide 
• 126645-58-7 N-(4-Benzyl-morpholin-2-ylmethyl)-3,5-dichloro-4-dimethylamino-2-hydroxy-benzamide 
• 126645-62-3 N-(4-Benzyl-morpholin-2-ylmethyl)-3,4,5-trimethoxy-benzamide 
• 126645-61-2 N-(4-Benzyl-morpholin-2-ylmethyl)-2,3,4,5,6-pentafluoro-benzamide 
• 112885-53-7 N-(4-Benzyl-morpholin-2-ylmethyl)-5-chloro-4-diethylamino-2-methoxy-benzamide 
• 112885-38-8 N-<(4-benzyl-2-morpholinyl)methyl>-3,4-(methylenedioxy)benzamide 
• 112885-51-5 N-(4-Benzyl-morpholin-2-ylmethyl)-5-chloro-4-dimethylamino-2-ethoxy-benzamide 
• 112885-55-9 N-<(4-benzyl-2-morpholinyl)methyl>-5-chloro-4-(dimethylamino)-2-methoxybenzamide 
• 112885-30-0 2,3-methylenedioxy-N-[(4-benzyl-2-morpholinyl)methyl]benzamide 
• 112885-49-1 N-(4-Benzyl-morpholin-2-ylmethyl)-5-chloro-4-dimethylamino-2-hydroxy-benzamide 
• 112885-58-2 N-(4-Benzyl-morpholin-2-ylmethyl)-5-chloro-2-methoxy-4-methylamino-benzamide 
• 112885-23-1 4-amino-N-<(4-benzyl-2-morpholinyl)methyl>-5-chloro-2-methoxybenzamide 
• 126645-57-6 4-Amino-N-(4-benzyl-morpholin-2-ylmethyl)-3-chloro-benzamide 

Relevant articles and documents

A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.

Pyrimidine derivatives

Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula STR1 wherein X is O or NR5, Y is O, S or NR5 wherein R5 is a hydrogen atom, a C1 -C6 alkyl group or the like; R1 and R2 may be the same or different and each is a hydrogen atom, a C1 -C6 alkyl group or the like; R3 is CN, or COOR6 wherein R6 is a C1 -C6 alkyl group, a C3 -C6 cycloalkyl group, an aryl group or the like; R4 is --SR7 or --NR8 R9 wherein R7 is a C1 -C6 alkyl group; R8 is a C1 -C6 alkyl group or the like; R9 is a hydrogen atom, a C1 -C6 alkyl group or the like, or R8 and R9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) STR2 wherein R10 represents a C1 -C6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.

Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides

With the purpose of obtaining more potent and selective gastric prokinetic agents than metoclopramide (1), a new series of N-[(2-morpholinyl)alkyl]benzamides (17-52) were synthesized and their gastric prokinetic activity was evaluated by determining effect on the gastric emptying of phenol red semisolid meal and of resin pellets solid meal in rats and mice. The morpholinyl moiety was newly designed after consideration of the side-chain structure of cisapride (2) and produced the desired activity when coupled with the 4-amino-5-chloro-2-methoxybenzoyl group of both metoclopramide and cisapride. Modification of the substituents of the benzoyl group markedly influenced the activity. In particular, 4-amino-N-[benzyl-2-morpholinyl)methyl]-5-chloro-2-methoxybenzamide (17) and the 4-(dimethylamino) and 2-ethoxy analogues (25 and 29) or 17 showed potent and selective gastric prokinetic activity along with a weak dopamine D2 receptor antagonistic activity.